- Home
- ORKA
as 04-02-2025 4:00pm EST
Oruka Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. The company's co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. These programs each bind their respective targets at high affinity and incorporate half-life extension technology to increase exposure and decreasing dosing frequency.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MENLO PARK |
| Market Cap: | 429.4M | IPO Year: | N/A |
| Target Price: | $39.67 | AVG Volume (30 days): | 248.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.95 - $53.88 | Next Earning Date: | 03-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Oruka Therapeutics Inc. Common Stock News
ORKA Breaking Stock News: Dive into ORKA Ticker-Specific Updates for Smart Investing
Simply Wall St.
a month ago
We're Not Very Worried About Oruka Therapeutics' (NASDAQ:ORKA) Cash Burn Rate
GlobeNewswire
a month ago
Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting
GlobeNewswire
a month ago
Oruka Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
a month ago
Oruka Therapeutics to Present at Multiple March Investor Conferences
TipRanks
3 months ago
Oruka Therapeutics doses first participants in Phase 1 trial of ORKA-001
GlobeNewswire
3 months ago
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
GlobeNewswire
4 months ago
Oruka Therapeutics to be Added to the Nasdaq Biotechnology Index (NBI)
Simply Wall St.
4 months ago
Oruka Therapeutics, Inc. (NASDAQ:ORKA) institutional investors have had a good week as stock gains 15%
Compare ORKA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ORKA Oruka Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.